A practical strategy to subcutaneous administered in-situ gelling co-delivery system of arsenic and retinoic acid for the treatment of acute promyelocytic leukemia

Arsenic trioxide (ATO) combined with all trans retinoic acid (ATRA) is the first choice for the treatment of low and medium risk acute promyelocytic leukemia (APL). Clinical studies reported that the combination of ATO and ATRA could achieve a significant curative effect. However, the retinoic acid...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xiao, Yin, Weiwei, Widjaya, Andy Samuel, Yang, Yueying, Liu, Yunhu, Jiang, Yanyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Shenyang Pharmaceutical University 2021
Materias:
Original Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609443/
https://www.ncbi.nlm.nih.gov/pubmed/34849168
http://dx.doi.org/10.1016/j.ajps.2021.07.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609443/
https://www.ncbi.nlm.nih.gov/pubmed/34849168
http://dx.doi.org/10.1016/j.ajps.2021.07.003

Ejemplares similares